BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24870838)

  • 1. [Cytokines and myeloma bone disease].
    Abe M
    Clin Calcium; 2014 Jun; 24(6):871-8. PubMed ID: 24870838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cytokines in bone diseases. Cytokines and myeloma bone disease].
    Abe M
    Clin Calcium; 2010 Oct; 20(10):1474-80. PubMed ID: 20890028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Myeloma bone disease and RANKL signaling].
    Abe M
    Clin Calcium; 2011 Aug; 21(8):1167-74. PubMed ID: 21814021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mechanisms for formation of myeloma bone disease].
    Yata K; Abe M; Matsumoto T
    Clin Calcium; 2008 Apr; 18(4):438-46. PubMed ID: 18379024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Myeloma bone disease].
    Abe M
    Clin Calcium; 2014 Aug; 24(8):1159-68. PubMed ID: 25065867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mutual interaction between myeloma cells and bone marrow microenvironment].
    Abe M
    Rinsho Ketsueki; 2009 Jun; 50(6):453-60. PubMed ID: 19571504
    [No Abstract]   [Full Text] [Related]  

  • 7. [Mechanisms of myeloma-induced bone disease].
    Abe M
    Clin Calcium; 2016 May; 26(5):699-706. PubMed ID: 27117615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bone disease in multiple myeloma and its mechanism].
    Abe M
    Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Link between osteoclastogenesis, angiogenesis and myeloma expansion].
    Abe M
    Clin Calcium; 2008 Apr; 18(4):473-9. PubMed ID: 18379029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X; Huang Y; Collin-Osdoby P; Osdoby P
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
    Boissy P; Andersen TL; Abdallah BM; Kassem M; Plesner T; Delaissé JM
    Cancer Res; 2005 Nov; 65(21):9943-52. PubMed ID: 16267019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The natural flavonoid galangin inhibits osteoclastic bone destruction and osteoclastogenesis by suppressing NF-κB in collagen-induced arthritis and bone marrow-derived macrophages.
    Huh JE; Jung IT; Choi J; Baek YH; Lee JD; Park DS; Choi DY
    Eur J Pharmacol; 2013 Jan; 698(1-3):57-66. PubMed ID: 22985747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
    Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
    Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
    Sordillo EM; Pearse RN
    Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential contribution of osteoclast- and osteoblast-lineage cells to CpG-oligodeoxynucleotide (CpG-ODN) modulation of osteoclastogenesis.
    Amcheslavsky A; Hemmi H; Akira S; Bar-Shavit Z
    J Bone Miner Res; 2005 Sep; 20(9):1692-9. PubMed ID: 16059640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory T cells rapidly induce differentiation of human bone marrow stromal cells into mature osteoblasts.
    Rifas L; Arackal S; Weitzmann MN
    J Cell Biochem; 2003 Mar; 88(4):650-9. PubMed ID: 12577299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Wnt signaling in myeloma.].
    Abe M
    Clin Calcium; 2019; 29(3):349-355. PubMed ID: 30814381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on the pathogenesis of osteolysis in multiple myeloma patients.
    Giuliani N; Colla S; Rizzoli V
    Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.
    Abe M
    Int J Hematol; 2011 Oct; 94(4):334-343. PubMed ID: 22005835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.